Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 12,678 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,678 shares of the business’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $25.04, for a total transaction of $317,457.12. Following the completion of the transaction, the chief operating officer owned 27,569 shares of the company’s stock, valued at approximately $690,327.76. The trade was a 31.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Castle Biosciences Stock Up 21.7%

NASDAQ CSTL traded up $5.64 during mid-day trading on Tuesday, reaching $31.63. The stock had a trading volume of 1,513,556 shares, compared to its average volume of 287,583. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $35.84. The company has a fifty day moving average price of $23.45 and a 200 day moving average price of $20.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69. The stock has a market cap of $917.59 million, a PE ratio of -70.29 and a beta of 1.12.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.32. The firm had revenue of $83.04 million during the quarter, compared to analysts’ expectations of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.75%. Castle Biosciences has set its FY 2025 guidance at EPS. On average, research analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CSTL. Zacks Research raised Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday, October 30th. BTIG Research reissued a “buy” rating on shares of Castle Biosciences in a report on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $37.00 price objective on shares of Castle Biosciences in a research note on Tuesday, September 9th. Finally, Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.14.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its position in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after acquiring an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Castle Biosciences in the 3rd quarter worth approximately $35,000. CWM LLC boosted its holdings in shares of Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares during the period. Harbour Investments Inc. purchased a new position in shares of Castle Biosciences in the 1st quarter worth approximately $50,000. Finally, Jones Financial Companies Lllp boosted its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.